Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.

Daphne AngSeok Hwee KooYiong Huak ChanThean Yen TanGaik Hong SoonChin Kimg TanKenneth Weicong LinJaydeesh-Khanna Krishnasamy-BalasubramanianYu Jun Wong Rahul KumarRajesh RYiyuan TanPeng-Lan Jeannie OngYi-Lyn Jessica TanJames Weiquan LiAndrew Boon-Eu KwekTiing Leong Ang

Published in: Alimentary pharmacology & therapeutics (2022)

One-week vonoprazan-based triple therapy achieved comparable efficacy to 2-week PPI-based triple therapy and was well tolerated.

Keyphrases

helicobacter pylori
helicobacter pylori infection
clinical trial
randomized controlled trial
phase ii
mesenchymal stem cells
small molecule
placebo controlled
endoscopic submucosal dissection
gastroesophageal reflux disease
smoking cessation
electron transfer